Items Tagged ‘ruxolitinib’

June 21st, 2016

Jakafi Superior to Standard Treatment in Polycythemia Vera

By

Treatment with Jakafi® (ruxolitinib) was superior to best available treatment among patients with inadequately controlled polycythemia vera (PV). These results were recently presented at the 21st Congress of the European Hematology Association (EHA) in Copenhagen, Denmark. PV is a type of myeloproliferative neoplasm (MPN) in which the body produces a larger than normal amount of […]

View full entry

Tags: jakafi, mpn, Myeloproliferative Neoplasms MPN, News, polycythemia vera, PV, ruxolitinib


December 29th, 2015

All Symptomatic Polycythemia Vera Patients May Benefit From Treatment with a JAK2 Inhibitor

By

Patients with polycythemia vera (PV) experience significant symptoms characterized by fatigue, itching, night sweats, bone pain, fever, and undesired weight loss that contribute to a poor quality of life which is often under appreciated by family and providers. Until recently, PV patients’ only treatment options were phlebotomy and hydroxyurea (HU). However, the development and approval […]

View full entry

Tags: jakafi, Myeloproliferative Neoplasms MPN, News, polycythemia vera, PV, ruxolitinib, treatment


July 7th, 2015

Jakafi® Appears Safe and Effective in Long-Term Disease Control in Polycythemia Vera

By

In patients with polycythemia vera (PV), the drug Jakafi® (ruxolitinib) can help control disease at least one year. These findings were presented at the 20th Congress of the European Hematology Association in Vienna, Austria, June 11–14, 2015.[1] Polycythemia vera is a slow-growing type of blood cancer that belongs to a group of blood disorders called […]

View full entry

Tags: blood cancer, clinical trials, hydrea, jakafi, MPNs, Myeloproliferative Neoplasms MPN, News, polycythemia vera, PV, ruxolitinib


April 14th, 2015

Jakafi® Provides Important Symptom Relief in Patients with Polycythemia Vera

By

A Phase III trial finds that Jakafi® (ruxolitinib) more effectively controls symptoms than standard therapy for patients with polycythemia vera (PV). These findings were published in the New England Journal of Medicine. Polycythemia vera is a slow-growing type of blood cancer that belongs to a group of blood disorders called myeloproliferative neoplasms (MPN). In these […]

View full entry

Tags: blood cancer, hydrea, hydroxyurea, improvement, jakafi, mpn, myeloproliferative neoplasms, Myeloproliferative Neoplasms MPN, News, ruxolitinib


February 17th, 2015

Phase III Trial Finds Jakafi Superior to Standard Therapy for Polycythemia Vera

By

A Phase III trial finds that Jakafi® (ruxolitinib) is more effective than standard therapy for patients with polycythemia vera (PV). These findings were published in the New England Journal of Medicine. Polycythemia vera is a slow-growing type of blood cancer that belongs to a group of blood disorders called myeloproliferative neoplasms (MPN). In these disorders, […]

View full entry

Tags: hydrea, hydroxyurea, jak1, JAK2, jakafi, mpn, Myeloproliferative Neoplasms MPN, myeloproliferative neoplastms, News, polycythemia vera, PV, PV treatment


December 16th, 2014

Jakafi® Helps Maintain Blood Cells Levels in Polycythemia Vera

By

CancerConnect News: A new drug called Jakafi® (ruxolitinib) appears to help patients with polycythemia vera (PV) maintain hematocrit control more effectively than best available therapy. These findings were presented at the 56th American Hematology Society Annual Meeting and Exposition, December 6–9, 2014, in San Francisco, California.[1] Polycythemia vera is a slow-growing type of blood cancer […]

View full entry

Tags: jakafi, mpn, myeloproliferative neoplasms, Myeloproliferative Neoplasms MPN, News, polycythemia vera, PV, ruxolitinib


December 11th, 2014

Jakafi® Appears Effective in the Treatment of Essential Thrombocythemia

By

By interfering with protein signaling linked to blood cell production, Jakafi® (ruxolitinib) may be effective in the treatment of essential thrombocythemia (ET) in patients who progress on or can’t tolerate Hydrea® (hydroxyurea). These findings were presented at the 56th American Hematological Society Annual Meeting and Exposition, December 6–9, 2014, in San Francisco, California. Essential thrombocythemia […]

View full entry

Tags: jakafi, mpn, myeloproliferative neoplasms, Myeloproliferative Neoplasms MPN, News, ruxolitinib


August 6th, 2014

FDA Accepts Supplemental New Drug Application for Jakafi and Priority Review Granted for the Treatment of Polycythemia Vera

By

The  U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) for Jakafi® (ruxolitinib) as a potential treatment of patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea. PV is a myeloproliferative neoplasm (MPN) characterized by an overproduction of normal red […]

View full entry

Tags: Info Type, jakafi, mpn, Myeloproliferative Neoplasms MPN, News, polycythemia vera, PV, ruxolitinib


June 6th, 2014

Jakafi Improves Hematocrit Control and Reduces Spleen Volume in Polycythemia Vera Patients

By

In a randomized phase 3 study of polycythemia vera (PV) patients, researchers determined that Jakafi® (ruxolitinib) was well tolerated and better controlled hematocrit ratios (ratio of red blood cell volume to total blood volume) than did the best available therapy. Jakafi was also successful in reducing spleen volume and improving PV symptoms. PV is a […]

View full entry

Tags: jakafi, mpn, Myeloproliferative Neoplasms MPN, News, polycythemia vera, ruxolitinib


June 2nd, 2014

Jakafi Plus Capecitabine Improves Survival in Metastatic Pancreatic Cancer Patients with Local and Systemic Inflammation

By

In a study presented at the 2014 ASCO meeting and published in the Journal of Clinical Oncology, researchers reported that treatment with Jakafi® (ruxolitinib) plus capecitabine improved overall survival and progression-free survival in metastatic pancreatic cancer patients with local and systemic inflammation (INFL). INFL is a common marker of cancer that is associated with adverse prognoses […]

View full entry

Tags: jakafi, News, Pancreatic Cancer, ruxolitinib, Stage IV Pancreatic Cancer, Stages I-III Pancreatic Cancer